Menu

Press Statements

Media Room Menu

Archives: Search / 2020 / 2019 / 2017 / 2016 / 2015 / 2013

 
  
From   
To   
 
 
Dec 21, 2020
Sanofi Pasteur Statement On YF-Vax® Vaccine Supply & Stamaril® Importation
[auto] More
Jul 22, 2020
Sanofi begins shipping flu vaccines in U.S. for 2020-2021 season
[auto] More
Oct 24, 2019
Availability of Sanofi Pasteur 2019-2020 Influenza Vaccines
[auto] More
Apr 10, 2019
U.S. House Hearing on Insulin Pricing
[auto] More
Mar 7, 2019
FDA Advisory Committee votes on Sanofi’s Dengvaxia® vaccine candidate for prevention of dengue in the United States
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) today voted on the safety and effectiveness of Dengvaxia® (Dengue... More
Feb 26, 2019
U.S. Senate Committee on Finance’s Hearing on Drug Pricing
summary More
Dec 19, 2017
Voluntary Recall of Synvisc-One Lot 7RSL021
On December 11, 2017, Sanofi Genzyme initiated a voluntary product recall for a single lot of Synvisc-One® (hylan G-F 20) lot 7RSL021 due to an ongoing investigation which revealed the presence... More
Oct 6, 2017
Sanofi Pasteur Closes Emergent Acquisition of Smallpox Vaccine
Sanofi Pasteur confirms that it has sold its ACAM2000® Smallpox Vaccine, Live assets, which include the Canton, MA and Rockville, MD facilities where the product is manufactured to Emergent.... More
Sep 1, 2017
Sanofi Statement on Zika Vaccine License
On August 17, 2017, Sanofi Pasteur was informed by The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in... More
Jul 24, 2017
Kathleen Tregoning Letter to the Editor Regarding Accessibility of Medicines
This letter was originally published by The New York Times on July 24, 2017 The Drug Maker Sanofi’s New Dengue Vaccine To the Editor: Fran Quigley made an extraordinary claim in “Escaping Big... More
Jul 24, 2017
Kathleen Tregoning Letter to the Editor Regarding Accessibility of Medicines
This letter was originally published by The New York Times on July 24, 2017 The Drug Maker Sanofi’s New Dengue Vaccine To the Editor: Fran Quigley made an extraordinary claim in “Escaping Big... More
Jul 16, 2017
Sanofi Response to U.S. Senators Regarding Investigational Zika Vaccine
Sanofi Response to Senator Blumenthal Sanofi Response to Senator Brown Sanofi Response to Senator Durbin Sanofi Response to Senator King Sanofi Response to Senator Markey Sanofi Response to... More
Jul 14, 2017
Sanofi Scientists Discuss Investigational Zika Vaccine
More
Jul 14, 2017
Sanofi Response to U.S. Senators Regarding Investigational Zika Vaccine
Sanofi Response to Senator Blumenthal Sanofi Response to Senator Brown Sanofi Response to Senator Durbin Sanofi Response to Senator King Sanofi Response to Senator Markey Sanofi Response to... More
Jul 14, 2017
Sanofi Letter to U.S. Army on Developing a Zika Vaccine
More
Jul 12, 2017
Sanofi Letter to U.S. Army on Developing a Zika Vaccine
More
Jun 27, 2017
Elias Zerhouni Letter to the Editor Regarding Developing a Zika Vaccine
This letter was originally published by The New York Times on March 21, 2017 Developing a Zika Vaccine To the Editor: Re ''Trump Should Avoid a Bad Zika Deal'' (Op-Ed, March 11): Bernie Sanders,... More
May 25, 2017
Sanofi Letter Submitted to the Energy and Commerce Oversight Hearing on Zika
More
Mar 21, 2017
Elias Zerhouni Letter to the Editor Regarding Developing a Zika Vaccine
This letter was originally published by The New York Times on March 21, 2017 Developing a Zika Vaccine To the Editor: Re ''Trump Should Avoid a Bad Zika Deal'' (Op-Ed, March 11): Bernie Sanders,... More
Feb 9, 2017
Sanofi Pasteur Commends the CDC for Updates Made to the 2017 Children and Adolescent Immunization Schedule
Sanofi Pasteur commends the U.S. Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices for updates made to the 2017 Children and Adolescent... More
Feb 9, 2017
Sanofi Pasteur Statement on the Discontinuation of Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
Sanofi Pasteur is discontinuing the production of Menomune®, its quadrivalent A, C, Y and W-135 polysaccharide meningococcal vaccine. Sanofi Pasteur will withdraw the Menomune® vaccine license... More
Jan 13, 2017
Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent® (alirocumab) Injection
Sanofi and Regeneron have filed a motion with the Federal Circuit Court of Appeals to stay (suspend) the injunction pending the appeal, and requested expedited consideration of our appeal by the... More
Jan 9, 2017
Sanofi and Regeneron Provide Update on Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Today the district court denied our motion to suspend the injunction, thus clearing the way for us to take our case to the Federal Circuit Court of Appeals. We will soon file a motion with the... More
Nov 21, 2016
Sanofi Pasteur Statement on Discontinuation of BCG
November 21, 2016 - Sanofi Pasteur has undertaken significant steps to restore production of ImmuCyst®/TheraCys® and to explore solutions to maintain the long-term availability of the product,... More
Nov 4, 2016
Sanofi Response to Insulin Pricing
Sanofi fully understands that the price and affordability of our products is important for patients. We have not increased the list price of Lantus since November 2014. In fact, the net price of... More
1-25      26-28